Daptomycin for methicillin-resistant staphylococcus aureus bloodstream infection and elevated vancomycin minimum inhibitory concentrations: Has the time come?

Clinical Infectious Diseases

Volumn 54, Issue 1, 2012, Pages 59-61

  Weston, Adam ^a,b   Boucher, Helen W ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BLOODSTREAM INFECTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84555206655     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir777     Document Type: Note

References (14)

1. Moore et al. Daptomycin versus vancomyin for MRSA bloodstream infections with high vancomycin MIC: A case control study. Clin Inf Dis 2011; 54:51-8.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
3. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-81.
4. Holmes N, Turnidge J, Munckhof W, et al. Antibiotic choice may not explain poor outcomes in patients with high vancomycin MIC Staphylococcus aureus bacteremia. J Infect Dis 2011; 204:340-7.
5. Walraven CJ, North MS, Marr-Lyon L, et al. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66:2386-92.
6. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200. (Pubitemid 351269157)
7. Cosgrove SE, Fowler VG. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 47:437.
8. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123:631-7.
9. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44. (Pubitemid 44631403)
10. Mohammedi I, Descloux E, Argaud L, Le Scanff J, Robert D. Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg. Int J Antimicrob Agents 2006; 27:259-62. (Pubitemid 43246959)
11. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacist. Am J Health Syst Pharm 2009; 66:82-98.
12. Lodise TP, Patel N, Lomaestro B, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-14.
13. Study of daptomycin safety and efficacy for complicated skin and skin structure infections (cSSSI) and bacteremia in renal impairment (RENSE). NCT01104662. Available at: http://www.clinicaltrials.gov. Accessed 10 August 2011.
14. Thomson Healthcare/Thomson PDR. Red book: pharmacy's fundamental reference. 2010; PDR Network, LLC, Montvale, NJ. Accessed 15 August 2011.